Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Peritoneal Neoplasms × talimogene laherparepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 3 Triple Negative Breast Neoplasms 2 Carcinoma, Squamous Cell 2 Carcinoma, Merkel Cell 2 Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Sarcoma 1 Rectal Neoplasms 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Neurofibromatosis 1 1 Neurofibromatoses 1 Neurofibroma 1 Neoplasm Metastasis 1 Mycosis Fungoides 1 Lymphoma, T-Cell, Cutaneous 1 Colorectal Neoplasms 1 Carcinoma, Basal Cell 1 Breast Carcinoma In Situ 1 Advanced Non CNS Tumors 1 Adenocarcinoma 1

Interventions

Cisplatin 7 Oxaliplatin 5 Paclitaxel 4 Fluorouracil 4 Carboplatin 3 Albumin-Bound Paclitaxel 3 Taxes 2 Nivolumab 2 Mitomycin 2 Leucovorin 2 Doxorubicin 2 130-nm albumin-bound paclitaxel 2 veliparib 1 tremelimumab 1 talimogene laherparepvec 1 soluble LAG-3 protein, human 1 sodium thiosulfate 1 pembrolizumab 1 nintedanib 1 irinotecan sucrosofate 1 durvalumab 1 dehydroftorafur 1 cc-486 1 avelumab 1 Trastuzumab 1 Radiotherapy 1 Radiation 1 Platinum 1 Pharmacogenomic Variants 1 Mitozytrex 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03663712 2024-11-20

TEMPO

Duke University

Phase 1 Completed

28 enrolled 10 charts

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡